|
08 Oct 2020 |
Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
|
|
08 Oct 2020 |
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
|
|
04 Oct 2020 |
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
|
|
02 Oct 2020 |
EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
|
|
02 Oct 2020 |
Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™ for the Treatment of Solid Tumors
|
|
01 Oct 2020 |
Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
|
|
29 Sep 2020 |
Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
|
|
29 Sep 2020 |
Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism
|
|
25 Sep 2020 |
NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12
|
|
25 Sep 2020 |
Molecular Partners Presents Preclinical Data Supporting Tumor Localization Mechanism of its CD40 Agonist MP0317 at World Bispecific Summit
|
|
23 Sep 2020 |
First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout
|
|
22 Sep 2020 |
Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial
|
|
22 Sep 2020 |
Micreos initiates clinical trial to evaluate world's first endolysin-drug as a therapy for Atopic Dermatitis
|
|
18 Sep 2020 |
Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications
|
|
18 Sep 2020 |
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
|
|
16 Sep 2020 |
Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12™ for the Treatment of Cancer
|
|
16 Sep 2020 |
Takeda to Divest TachoSil® to Corza Health for €350 Million
|
|
14 Sep 2020 |
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
|
|
14 Sep 2020 |
Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
|
|
14 Sep 2020 |
Molecular Partners Completes GMP Manufacturing of Anti-COVID-19 DARPin® Candidate MP0420 for Clinical Use
|
|
12 Sep 2020 |
Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
|
|
12 Sep 2020 |
Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
|
|
11 Sep 2020 |
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors
|
|
10 Sep 2020 |
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration
|
|
09 Sep 2020 |
Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency
|
